Skip to main content
. Author manuscript; available in PMC: 2023 Jan 20.
Published in final edited form as: Nat Biotechnol. 2022 Oct 10;41(1):128–139. doi: 10.1038/s41587-022-01474-0

Fig. 3 |. Discovery of interactome-based host-targeting therapies for COVID-19.

Fig. 3 |

a, Work flow of drug repurposing for COVID-19 using our interactome. We ranked the drugs by their proximity to the SARS-CoV-2 host factors (Supplementary Table 7), filtered the top drugs by their NCATS anti-SARS-CoV-2 profiles (Supplementary Table 8) and finally analyzed their drug–outcome relationship using EHR data (Table 1 and Supplementary Table 9,10). b, The top 23 drugs can target the SARS-CoV-2 host factors directly or through protein–protein interactions with their targets.